Calm Before The Storm: Pharma Opens 2019 With A Bang In China

 
• By Brian Yang

Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.

China flag with arrow graph going up showing strong economy and shares rise. Profit and success. Isolated vector illustration.
PHARMA SMASHES Q1 IN CHINA BUT PRICING UNCERTAINTY CLOUDS FORECAST • Source: Shutterstock

More from China

More from Focus On Asia